NEOS Investment Management LLC Lowers Stock Holdings in argenx SE (NASDAQ:ARGX)

NEOS Investment Management LLC lowered its position in shares of argenx SE (NASDAQ:ARGX) by 2.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,598 shares of the company’s stock after selling 106 shares during the period. NEOS Investment Management LLC’s holdings in argenx were worth $2,828,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Steward Partners Investment Advisory LLC increased its stake in argenx by 5.6% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock worth $234,000 after acquiring an additional 20 shares during the last quarter. SG Americas Securities LLC raised its stake in argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after purchasing an additional 21 shares in the last quarter. Farther Finance Advisors LLC raised its stake in argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after purchasing an additional 21 shares in the last quarter. Dynasty Wealth Management LLC lifted its position in argenx by 3.4% during the fourth quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after purchasing an additional 22 shares during the last quarter. Finally, Choreo LLC increased its holdings in shares of argenx by 4.4% in the 4th quarter. Choreo LLC now owns 551 shares of the company’s stock worth $342,000 after buying an additional 23 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Stock Down 0.7 %

Shares of ARGX stock opened at $589.15 on Friday. The firm has a market capitalization of $35.80 billion, a price-to-earnings ratio of -669.49 and a beta of 0.59. The stock has a fifty day moving average of $628.26 and a 200 day moving average of $601.20. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million during the quarter, compared to analysts’ expectations of $678.52 million. Equities research analysts anticipate that argenx SE will post 3.13 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on ARGX shares. Guggenheim upped their target price on shares of argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Oppenheimer increased their price objective on argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. HC Wainwright boosted their target price on argenx from $717.00 to $720.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. William Blair reiterated an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Finally, Sanford C. Bernstein upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a report on Monday, March 17th. Three equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $687.00.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.